GB9501841D0
(en)
*
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
GB9515182D0
(en)
*
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US20070212422A1
(en)
*
|
1999-11-10 |
2007-09-13 |
Manfred Keller |
Dry powder for inhalation
|
US20060171899A1
(en)
*
|
1998-12-10 |
2006-08-03 |
Akwete Adjei |
Water-stabilized aerosol formulation system and method of making
|
PL196951B1
(pl)
*
|
1999-03-05 |
2008-02-29 |
Chiesi Farma Spa |
Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
|
IT1309592B1
(it)
*
|
1999-03-05 |
2002-01-24 |
Chiesi Farma Spa |
Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
|
PE20011227A1
(es)
*
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
GB0009468D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
GB0012261D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel process
|
GB0012260D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel composition
|
WO2002000197A1
(fr)
|
2000-06-27 |
2002-01-03 |
Vectura Limited |
Procede permettant de produire des particules destinees a etre utilisees dans une composition pharmaceutique
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
EP2283818B1
(fr)
|
2000-11-30 |
2017-08-02 |
Vectura Limited |
Procede de preparation de particules destinees a etre utilisees dans une composition pharmaceutique
|
WO2002043700A2
(fr)
*
|
2000-11-30 |
2002-06-06 |
Vectura Limited |
Particules servant dans une composition pharmaceutique
|
NZ526059A
(en)
†
|
2000-11-30 |
2005-05-27 |
Vectura Ltd |
Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
|
WO2002056948A1
(fr)
|
2001-01-17 |
2002-07-25 |
Vectura Limited |
Dispositif d'inhalation
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
WO2003024396A2
(fr)
|
2001-09-17 |
2003-03-27 |
Glaxo Group Limited |
Formulations de medicament en poudre seche
|
US7931533B2
(en)
|
2001-09-28 |
2011-04-26 |
Igt |
Game development architecture that decouples the game logic from the graphics logics
|
SE0200312D0
(sv)
|
2002-02-01 |
2002-02-01 |
Astrazeneca Ab |
Novel composition
|
EP1498116A1
(fr)
*
|
2002-03-20 |
2005-01-19 |
Hosokawa Micron Corporation |
Procede de fabrication de particules composites contenant un produit chimique
|
FI116657B
(fi)
*
|
2002-03-28 |
2006-01-31 |
Focus Inhalation Oy |
Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
|
US20030235538A1
(en)
*
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US8273331B2
(en)
*
|
2002-08-21 |
2012-09-25 |
Norton Healthcare Ltd. |
Inhalation compositions
|
WO2004028545A1
(fr)
*
|
2002-09-25 |
2004-04-08 |
Astrazeneca Ab |
Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1452179A1
(fr)
*
|
2003-02-27 |
2004-09-01 |
CHIESI FARMACEUTICI S.p.A. |
Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
|
US20060147389A1
(en)
*
|
2004-04-14 |
2006-07-06 |
Vectura Ltd. |
Devices and pharmaceutical compositions for enhancing dosing efficiency
|
WO2004093848A2
(fr)
*
|
2003-04-14 |
2004-11-04 |
Vectura Ltd |
Dispositifs et compositions pharmaceutiques destines a ameliorer l'efficacite de dosage
|
US7094545B2
(en)
|
2003-04-30 |
2006-08-22 |
Ferring Bv |
Pharmaceutical composition as solid dosage form and method for manufacturing thereof
|
EP1643973A1
(fr)
*
|
2003-07-11 |
2006-04-12 |
Glaxo Group Limited |
Preparations pharmaceutiques contenant du stearate de magnesium
|
JP2009514779A
(ja)
*
|
2003-07-11 |
2009-04-09 |
グラクソ グループ リミテッド |
医薬製剤
|
DK1500390T3
(da)
|
2003-07-25 |
2005-09-19 |
Ferring Bv |
Farmaceutisk præparat som fast dosisform og fremgangsmåde til fremstilling deraf
|
CN1826099B
(zh)
*
|
2003-07-25 |
2010-06-09 |
凡林有限公司 |
固体剂型药物组合物及其制造方法
|
WO2005025535A2
(fr)
*
|
2003-09-15 |
2005-03-24 |
Vectura Limited |
Procedes de preparation de compositions pharmaceutiques
|
GB0321607D0
(en)
*
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
GB0324918D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Glaxo Group Ltd |
Composition
|
GB0326632D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Jagotec Ag |
Dry powder formulations
|
SE0303569L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
DPI för avlämning av fuktkänsliga medikament
|
SE0303269L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Medicinsk produkt
|
SE0303270L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Metod för administration av tiotropium
|
CA2547782A1
(fr)
*
|
2003-12-03 |
2005-06-16 |
Microdrug Ag |
Produit medical contenant du tiotropium
|
SE0303570L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Fukt-känslig medicinsk produkt
|
SE0303571D0
(sv)
*
|
2003-12-03 |
2003-12-22 |
Microdrug Ag |
Medical product for moisture-sensitive medicaments
|
US7018653B2
(en)
|
2003-12-29 |
2006-03-28 |
Ferring B.V. |
Method for preparing solid dosage form of desmopressin
|
JO3102B1
(ar)
*
|
2004-03-17 |
2017-09-20 |
Chiesi Framaceutici S P A |
صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
|
EP2708225B1
(fr)
*
|
2004-04-23 |
2018-12-26 |
CyDex Pharmaceuticals, Inc. |
Formulation DPI contenant de la cyclodextrine d'éther de sulfoalkyle
|
GB0409703D0
(en)
|
2004-04-30 |
2004-06-02 |
Vectura Ltd |
Pharmaceutical compositions
|
GB0425758D0
(en)
|
2004-11-23 |
2004-12-22 |
Vectura Ltd |
Preparation of pharmaceutical compositions
|
GB0426301D0
(en)
*
|
2004-11-30 |
2004-12-29 |
Vectura Ltd |
Pharmaceutical formulations
|
ES2613391T3
(es)
|
2005-02-10 |
2017-05-24 |
Glaxo Group Limited |
Procedimientos de fabricación de lactosa que utilizan técnicas de preclasificación y formulaciones farmacéuticas formadas a partir de la misma
|
WO2006095788A1
(fr)
*
|
2005-03-09 |
2006-09-14 |
Ono Pharmaceutical Co., Ltd. |
Particule et preparation la contenant
|
EP2484382A1
(fr)
*
|
2005-03-30 |
2012-08-08 |
Schering Corporation |
Médicament à base d'un inhibiteur de la phosphodiestérase IV sous une forme adaptée à l'inhalation
|
TWI274641B
(en)
*
|
2005-08-30 |
2007-03-01 |
Rexon Ind Corp Ltd |
Cutting machine
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
GB0525254D0
(en)
|
2005-12-12 |
2006-01-18 |
Jagotec Ag |
Powder compositions for inhalation
|
GB0613161D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic Compounds
|
GB0622818D0
(en)
*
|
2006-11-15 |
2006-12-27 |
Jagotec Ag |
Improvements in or relating to organic compounds
|
EP1944018A1
(fr)
*
|
2007-01-10 |
2008-07-16 |
CHIESI FARMACEUTICI S.p.A. |
Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
|
PL2425820T3
(pl)
|
2007-02-11 |
2015-08-31 |
Map Pharmaceuticals Inc |
Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
|
KR20100044225A
(ko)
|
2007-07-21 |
2010-04-29 |
알바니 몰레큘라 리써치, 인크. |
5-피리디논 치환된 인다졸
|
EP2674417A3
(fr)
|
2007-11-21 |
2014-04-09 |
Decode Genetics EHF |
Inhibiteurs de pde4 biaryle pour le traitement de l'inflammation
|
ES2523580T3
(es)
|
2008-01-11 |
2014-11-27 |
Albany Molecular Research, Inc. |
Piridoindoles substituidos con (1-Azinona)
|
WO2009088054A1
(fr)
|
2008-01-11 |
2009-07-16 |
Astellas Pharma Inc. |
Modèle animal ayant à la fois une douleur dans les testicules ou des actions d'inconfort en relation aux testicules et une miction fréquente
|
EP2080508A1
(fr)
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Formulation de poudre sèche comprenant un médicament anticholinérgique
|
WO2010059836A1
(fr)
|
2008-11-20 |
2010-05-27 |
Decode Genetics Ehf |
Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
|
EP2191821A1
(fr)
*
|
2008-11-26 |
2010-06-02 |
CHIESI FARMACEUTICI S.p.A. |
Microparticles contenant une sel de 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone avec adhesion ameliorée pour l'inhalation de poudre sèche
|
CA2750777C
(fr)
|
2009-01-26 |
2018-04-03 |
Israel Institute For Biological Research |
Composes spiro heterocycliques bicycliques
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2010097188A1
(fr)
*
|
2009-02-25 |
2010-09-02 |
Chiesi Farmaceutici S.P.A. |
Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
|
DK2400950T3
(da)
|
2009-02-26 |
2019-07-29 |
Glaxo Group Ltd |
Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
|
US20120101077A1
(en)
*
|
2009-04-24 |
2012-04-26 |
Schering Corporation |
Agglomerate formulations useful in dry powder inhalers
|
WO2011015289A1
(fr)
|
2009-08-04 |
2011-02-10 |
Chiesi Farmaceutici S.P.A. |
Hémi-fumarate de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1h)-quinolinone
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
EP2360147A1
(fr)
|
2010-02-22 |
2011-08-24 |
CHIESI FARMACEUTICI S.p.A. |
Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
|
RU2585101C2
(ru)
|
2010-04-01 |
2016-05-27 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Способ приготовления частиц носителя для сухих порошков для ингаляции
|
PL2560611T3
(pl)
*
|
2010-04-21 |
2018-05-30 |
Chiesi Farmaceutici S.P.A. |
Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych
|
DK2563813T3
(en)
|
2010-04-30 |
2015-11-30 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods of use of antibodies
|
US9259376B2
(en)
|
2010-06-03 |
2016-02-16 |
Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. |
Process for dry powder formulations
|
BR112012032330A2
(pt)
|
2010-06-22 |
2016-11-08 |
Chiesi Farma Spa |
formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
|
SI2600830T1
(en)
|
2010-08-03 |
2018-05-31 |
Chiesi Farmaceutici S.P.A. |
A dry powder formulation comprising a phosphodiesterase inhibitor
|
US20130177651A1
(en)
*
|
2010-09-03 |
2013-07-11 |
Pharmaterials Limited |
Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler
|
CA2812414C
(fr)
|
2010-09-29 |
2020-09-22 |
Pulmatrix, Inc. |
Poudres seches a cations metalliques monovalents pour inhalation
|
RU2580890C2
(ru)
|
2010-09-30 |
2016-04-10 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Применение стеарата магния в составах сухого порошка для ингаляции
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
TR201105367A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
|
TR201205852A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Geliştirilmiş yeni kuru toz formülasyonu.
|
WO2013109215A1
(fr)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Préparation de formulations en poudre sèche comprenant du formotérol
|
WO2013109211A1
(fr)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
|
WO2013109210A1
(fr)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Formulations en poudre sèche comprenant du budésonide
|
KR101560288B1
(ko)
|
2012-01-25 |
2015-10-14 |
키에시 파르마슈티시 엣스. 피. 에이. |
흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
|
WO2013114371A1
(fr)
|
2012-02-01 |
2013-08-08 |
Protalix Ltd. |
Formulation en poudre sèche de dnase i
|
JP2015509788A
(ja)
|
2012-02-29 |
2015-04-02 |
パルマトリックス,インコーポレイテッド |
吸入に適した乾燥粉末
|
PL2834244T3
(pl)
|
2012-03-13 |
2017-01-31 |
Respivert Limited |
Krystaliczne inhibitory kinaz PI3
|
KR20140147891A
(ko)
|
2012-04-13 |
2014-12-30 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
응집체 입자
|
WO2014007771A2
(fr)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
|
WO2014007772A2
(fr)
*
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Compositions d'inhalation contenant du glucose anhydre
|
CN109846862A
(zh)
|
2012-10-25 |
2019-06-07 |
通用医疗公司 |
治疗阿尔茨海默病及相关疾病的组合疗法
|
US11052202B2
(en)
|
2012-11-07 |
2021-07-06 |
Chiesi Farmaceutici S.P.A. |
Drug delivery device for the treatment of patients with respiratory diseases
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
EP3763366A1
(fr)
|
2013-01-28 |
2021-01-13 |
Incozen Therapeutics Pvt. Ltd. |
N-oxyde de roflumilast pour l'utilisation dans le traitement de troubles auto-immuns, respiratoires et inflammatoires par inhalation
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
WO2014160958A1
(fr)
|
2013-03-29 |
2014-10-02 |
Alexion Pharmaceuticals, Inc. |
Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire
|
WO2014178891A1
(fr)
|
2013-04-30 |
2014-11-06 |
Otitopic Inc. |
Formulations de poudre sèche et procédés d'utilisation
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
PL2821061T3
(pl)
*
|
2013-07-01 |
2018-05-30 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Nowe preparaty do inhalacji
|
DK3409270T3
(da)
|
2013-07-11 |
2021-04-26 |
Chiesi Farm Spa |
Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation
|
EP3052092A2
(fr)
*
|
2013-10-02 |
2016-08-10 |
Vectura Limited |
Procédé et appareil
|
US9427376B2
(en)
|
2013-10-10 |
2016-08-30 |
Chiesi Farmaceutici S.P.A. |
Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
|
US10188757B2
(en)
|
2013-10-22 |
2019-01-29 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US9554992B2
(en)
|
2014-06-09 |
2017-01-31 |
Chiesi Farmaceutici S.P.A. |
Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
|
EP2957552B1
(fr)
|
2014-06-16 |
2020-01-22 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Formulations de vilanterol
|
TR201407010A2
(tr)
|
2014-06-16 |
2015-12-21 |
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi |
Vilanterol formülasyonları.
|
EP3166641B1
(fr)
|
2014-07-09 |
2018-09-12 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Procédé pour la préparation de formulations à inhaler
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
DK3212212T3
(da)
|
2014-10-31 |
2020-12-21 |
Univ Monash |
Pulverformulering
|
RU2693201C1
(ru)
*
|
2015-06-23 |
2019-07-01 |
Шлюмберже Текнолоджи Б.В. |
Распознание расклинивающего агента с помощью мобильного устройства
|
US11224594B2
(en)
*
|
2015-09-16 |
2022-01-18 |
Philip Morris Products S.A. |
Nicotine formulations and methods of making and using the same
|
JP6942126B2
(ja)
|
2015-11-16 |
2021-09-29 |
キエージ・フアルマチエウテイチ・エツセ・ピ・ア |
抗コリン作用薬、コルチコステロイド及びβ−アドレナリン作用薬を含む乾燥粉末製剤の製造方法
|
SI3620176T1
(sl)
|
2015-11-16 |
2021-11-30 |
Chiesi Farmaceutici S.P.A. |
Postopek za pripravo suhe praškaste formulacije, ki obsega antiholinergik, kortikosteroid in beta-andrenergik
|
ES2948157T3
(es)
|
2015-12-24 |
2023-09-01 |
Philip Morris Products Sa |
Cápsula de partículas de nicotina
|
US20190240194A1
(en)
|
2016-08-31 |
2019-08-08 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
PL3621590T3
(pl)
*
|
2017-05-11 |
2022-01-17 |
Chiesi Farmaceutici S.P.A. |
Sposób wytwarzania preparatu suchego proszku zawierającego środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny
|
MA48620A
(fr)
|
2017-05-11 |
2021-04-28 |
Chiesi Farm Spa |
Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
|
US10583085B2
(en)
*
|
2017-05-17 |
2020-03-10 |
Chiesi Farmaceutici S.P.A. |
Carrier particles for dry powder formulations for inhalation
|
SG11202000105QA
(en)
|
2017-07-14 |
2020-02-27 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies and uses thereof
|
EP3658033A4
(fr)
*
|
2017-07-26 |
2021-02-24 |
Shenzhen Xpectvision Technology Co., Ltd. |
Système doté d'une source de rayons x à expansion spatiale pour imagerie par rayons x
|
EP3658184B1
(fr)
|
2017-07-27 |
2023-09-06 |
Alexion Pharmaceuticals, Inc. |
Formules d'anticorps anti-c5 à haute concentration
|
WO2019060604A1
(fr)
|
2017-09-20 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Médicament inhalable
|
CN115919780A
(zh)
|
2017-09-22 |
2023-04-07 |
维克图拉公司 |
含有硬脂酸镁的干粉组合物
|
WO2019060797A1
(fr)
|
2017-09-22 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Procédé de fabrication de poudres à inhaler
|
US10786456B2
(en)
|
2017-09-22 |
2020-09-29 |
Otitopic Inc. |
Inhaled aspirin and magnesium to treat inflammation
|
WO2019067708A1
(fr)
*
|
2017-09-27 |
2019-04-04 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Procédé pour diminuer la taille de particules
|
WO2020010049A1
(fr)
*
|
2018-07-02 |
2020-01-09 |
The General Hospital Corporation |
FORMULATIONS EN POUDRE DE CROMOGLYCATE DE SODIUM ET D'α-LACTOSE
|
AU2019311268A1
(en)
|
2018-07-27 |
2021-02-11 |
Chiesi Farmaceutici S.P.A. |
Novel carrier particles for dry powder formulations for inhalation
|
AU2019334202A1
(en)
|
2018-09-06 |
2021-03-25 |
Innopharmascreen, Inc. |
Methods and compositions for treatment of asthma or parkinson's disease
|
MA54045A
(fr)
|
2018-10-30 |
2021-09-08 |
Chiesi Farm Spa |
Appareil pour administrer des médicaments à des patients ventilés mécaniquement
|
BR112021012172A2
(pt)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
Receptores de antígenos quiméricos e de célula t e métodos de uso
|
CA3138530A1
(fr)
|
2019-04-29 |
2020-11-05 |
Insmed Incorporated |
Compositions de poudre seche de promedicaments de treprostinil et methodes d'utilisation de celles-ci
|
EP4034079A1
(fr)
|
2019-09-24 |
2022-08-03 |
Chiesi Farmaceutici S.p.A. |
Nouvelles particules de support pour formulations de poudre sèche pour inhalation
|
EP4138911A1
(fr)
|
2020-04-24 |
2023-03-01 |
Millennium Pharmaceuticals, Inc. |
Anticorps anti-cd19 et leurs utilisations
|
WO2021237109A1
(fr)
|
2020-05-22 |
2021-11-25 |
Trailhead Biosystems Inc. |
Polythérapie pour le traitement d'infections virales
|
CN112451509B
(zh)
*
|
2020-12-19 |
2023-03-07 |
沈阳药科大学 |
一种川丁特罗吸入粉雾剂及其制备方法
|
EP4320149A1
(fr)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Anticorps ciblant le facteur d du complément et leurs utilisations
|
KR20240004287A
(ko)
|
2021-04-26 |
2024-01-11 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항-adgre2 항체 및 이의 용도
|
CA3216770A1
(fr)
|
2021-04-26 |
2022-11-03 |
Tomoki Yoshihara |
Anticorps anti-clec12a et leurs utilisations
|
IL311837A
(en)
|
2021-10-20 |
2024-05-01 |
Takeda Pharmaceuticals Co |
BCMA designated preparations and methods for their use
|
WO2023117985A1
(fr)
|
2021-12-21 |
2023-06-29 |
Chiesi Farmaceutici S.P.A. |
Formulations de poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
|
WO2023117967A1
(fr)
|
2021-12-21 |
2023-06-29 |
Chiesi Farmaceutici S.P.A. |
Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
|
WO2023150747A1
(fr)
|
2022-02-07 |
2023-08-10 |
Insmed Incorporated |
Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation
|
WO2024062007A1
(fr)
|
2022-09-22 |
2024-03-28 |
Chiesi Farmaceutici S.P.A. |
Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
|